INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial

Trials

Filippo Crea¹  Giovanni Schiavoni¹  Valentina Coluccia¹  Antonio Maria Leone¹  Giampaolo Niccoli¹  Gianluigi De Maria¹  Antonella Tommasino¹  Italo Porto¹  Carlo Trani¹  Marta Francesca Brancati¹  Francesco Burzotta¹ 

[1] Institute of Cardiology, Catholic University of the Sacred Heart, L.go Gemelli 8, 00168, Rome, Italy

关键词: Percutaneous coronary interventions;    Drug-eluting balloon;    Bare-metal stent;   

Others  :  1095596
DOI  :  10.1186/1745-6215-13-55

 received in 2011-05-08, accepted in 2012-05-06,  发布年份 2012

【 摘 要 】

Background

Neointimal hyperplasia plays a pivotal role in the pathogenesis of in-stent restenosis in patients undergoing percutaneous coronary interventions. Drug-eluting balloons are a promising tool to prevent restenosis after coronary angioplasty. Moreover, an increased knowledge of the pathophysiology of restenosis my help improve therapeutic strategies.

Methods/Design

We present the design of an open-label, randomized three-arm clinical trial aimed to assess whether a strategy of bare-metal stent implantation with additional use of drug-eluting balloons, either before (pre-dilation) or after stenting (post-dilation), reduces the primary endpoint of in-stent neointimal hyperplasia area as compared with a strategy of bare-metal stent implantation alone. This primary endpoint will be assessed by optical coherence tomography at follow-up. Secondary endpoints will be the percentage of uncovered struts, and the percentage of struts with incomplete apposition. An ancillary study investigating the relation between systemic levels of endothelial progenitors cells and neointimal hyperplasia, and the interaction between endothelial progenitors cell levels and drug-eluting balloons has been planned. Thirty consecutive patients undergoing percutaneous coronary intervention will be randomized with a 1:1:1 design to bare-metal stent implantation alone (n = 10); bare-metal stent implantation after pre-dilation with a drug-eluting balloon (n = 10); or bare-metal stent implantation followed by post-dilation with a drug-eluting balloon (n = 10). Six-month follow-up coronary angiography with optical coherence tomography imaging of the stented segment will be performed in all patients. Blood samples for the assessment of endothelial progenitors cell levels will be collected on admission and at 6 months.

Discussion

Experimental and early clinical data showed that inhibition of neointimal hyperplasia may be obtained by local administration of antiproliferative drugs loaded on the surface of angioplasty balloons. The INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO) trial was conceived to test the superiority of a strategy of bare-metal stent implantation with additional drug-eluting balloon use (either before or after stenting) versus a strategy of bare-metal stent implantation alone for the reduction of neointimal hyperplasia. We also planned an ancillary study to assess the role of endothelial progenitors cells in the pathophysiology of neointimal hyperplasia.

Trial registration

Clinicaltrials.gov NCT01057563.

【 授权许可】

   
2012 Burzotta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Waugh J, Wagstaff AJ: The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs 2004, 4:257-268.
• [2]Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R: Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
• [3]Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R: Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
• [4]King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O’Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW, ACC/AHA/SCA: 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008, 51:172-209.
• [5]Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G: Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004, 110:810-814.
• [6]Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B: Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009, 119(23):2986-2994.
• [7]Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U: Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006, 355:2113-2124.
• [8]Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U: Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008, 97:773-781.
• [9]Waksman R, Pakala R: Drug-eluting balloon. The comeback kid? Circ Cardiovasc Interven 2009, 2:352-358.
• [10]Maier LS, Maack C, Ritter O, Bohm M: Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008 (PEPCAD LokalTax, INH, German ablation registry, German device registry, DESDE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN). Clin Res Cardiol 2008, 97:356-363.
• [11]Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U: Paclitaxel-coated balloon versus drug-eluting stent durino PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010, 96:1291-1296.
• [12]Prati F, Cera M, Ramazzotti V, Imola F, Giudice R, Albertucci M: Safety and feasibility of a new non-occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisition in various clinical and anatomical scenarios. EuroInterv 2007, 3:365-370.
• [13]Chen BX, Ma FY, Luo W, Ruan JH, Xie WL, Zhao XZ, Sun SH, Guo XM, Wang F, Tian T, Chu XW: Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 2008, 94:566-570.
• [14]Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, Akasaka T, Costa M, Guagliumi G, Grube E, Ozaki Y, Pinto F, Serruys PW, Expert’s OCT Review Document: Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010, 31:401-415.
• [15]Gutierrez-Chico JL, van Geuns RJ, Koch KT, Koolen J, Duckers H, Regar E, Serruys PW: Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. Eurointervention 2011, 7(6):711-722.
• [16]George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, Michowitz Y, Miller H, Keren G: Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 2003, 23:e57-e60.
• [17]Pelliccia F, Cianfrocca C, Rosano G, Mercuro G, Speciale G, Pasceri V: Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. JACC Cardiovasc Interv 2010, 3:78-86.
• [18]Escolar E, Mintz GS, Popma J, Michalek A, Kim SW, Mandinov L, Koglin J, Stone G, Ellis SG, Grube E, Dawkins KD, Weissman NJ: Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V and VI). Am J Cardiol 2007, 10:621-626.
• [19]Kim J, Wallace-Bradley D, Alviar C, Conditt G, Milewski K, Afari ME, Cheng Y, Gallego C, Tellez A, Stone GW, Kaluza GL, Granada JF: Correlation of angiographic late loss with neointimal proliferation in stents evaluated by OCT and histology in porcine coronary arteries. J Am Coll Cardiol Img 2011, 4:1002-1010.
• [20]Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M: Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007, 28:961-967.
• [21]Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF: In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv 2008, 1:168-173.
• [22]Kubo T, Imanishi T, Kitabata H, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Takarada S, Tanaka A, Nakamura N, Mizukoshi M, Tomobuchi Y, Akasaka T: Comparison of vascular response after sirolimus eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study. J Am Coll Cardiol Img 2008, 1:475-484.
• [23]Bouma BE, Tearney GJ, Yabushita H, Shishkov M, Kauffman CR, DeJoseph Gauthier D, MacNeill BD, Houser SL, Aretz HT, Halpern EF, Jang IK: Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 2003, 89:317-320.
• [24]Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S: Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007, 115:2426-2434.
• [25]Guagliumi G, Sirbu V: Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008, 72:237-247.
• [26]Maehara A, Minz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Stone GW: Volumetric intravascular ultrasound analysis of paclitaxel-eluting and bare metal stents in acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Intravascular Ultrasound Substudy. Circulation 2009, 120:1875-1882.
• [27]Tatsuya I, Mitsuyasu T, Yoshihiro T: Optical coherence tomography analysis of neointimal stent coverage in sirolimus eluting stents compared with bare metal stents. American College of Cardiology Scientific Sessions 2006. J Am Coll Cardiol 2006, 47(Suppl):A2906-A2973.
• [28]Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, Mehran R, Stone GW: Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. Circulation 2011, 123:274-281.
• [29]Moore P, Barlis P, Spiro J, Ghimire G, Roughton M, Di Mario C, Wallis W, Ilsley C, Mitchell A, Mason M, Kharbanda R, Vincent P, Sherwin S, Dalby M: A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. JACC Cardiovasc Interv 2009, 2:437-444.
• [30]Porto I, Di Vito L, De Maria GL, Dato I, Tritarelli A, Leone AM, Niccoli G, Capogrossi MC, Biasucci LM, Crea F: Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. Am J Cardiol 2009, 103:1500-1505.